ADMA Adma Biologics Inc

$ADMA There was approx. $319.7M remaining in the share repurchase pot to buy shares starting from July 1. As of June 30, 16,539,353 shares were taken off the float. The avg price paid for these shares was $10.90. 225,355,228 and 237,874,496 shares of common stock were outstanding as of June 30, 2026 and December 31, 2025. The share repurchases therefore resulted in a 5.3% reduction of shares of common stock outstanding, improved share concentration, and will increase EPS. It will be interesting to hear how many shares were repurchased during the 3rd Q when ADMA reports ER results. ADMA Biologics is expected to report its next quarterly earnings (Q3 2026) on or around Wednesday, November 4, 2026, typically after market close. ADMA typically issues a formal press release confirming the exact date and conference call details approximately one to two weeks prior to the release.

$ADMA I believe there is a significant disconnect between the current share price and the underlying value of the company. This disconnect is not necessarily due to this being a speculative investment, in my view. On the contrary, it looks to me like the price reflects a loss of faith in management's ability to correctly forecast growth. If there are buyers with deep pockets who still believe in the growth story of ASCENIV, I would consider the possibility of said buyers being interested in making an attempt to buy this business for a hefty, yet reasonable premium before the market learns if the growth story of ASCENIV is proven to be real in the coming quarters. Within the last 12 months, we've seen the share price at more than double the current levels, and the short report, in concert with a weakening environment for BIVIGAM, created a perfect storm-like scenario wherein the share price cratered. I believe the worst is behind ADMA. Good luck everyone!

$ADMA ASCENIV & SG-001 ✔️ ADMA already traded above $23 last year (before much of the buyback), which is not far from $30 in today's terms. If we take into account the significant growth of the blockbuster potential ASCENIV franchise, with very strong margins (compared with other options), and SG-001 getting closer, we're talking about triple-digit potential over the next few/several years. The stock could re-rate significantly higher very quickly as ASCENIV continues delivering strong growth and margins, while constant buybacks provide additional support. ADMA is already a highly profitable biotech, and when SG-001 is ready to go, we're potentially looking at a company with a leadership position in the plasma industry.

$ADMA Still holding 60K shares. Re-reading the previous quarterly report helps me look forward especially since these guys lack a PR machine. 1st half revenue 239M, 2nd half estimate 291M to 321M. 1st half adjusted net income 80M, 2nd half estimate 90M - 120M. Asceniv continues to compound growth with each new physician/patient due to the recurring nature of the treatment. June had the strongest Asceniv growth in 2yrs. Share repurchases continue totaling almost 14M shares already this year with more to come. In May 2025 the board authorized $500 Million repurchase.

$ADMA I don’t understand this stock and how it moves . This is why I stay invested instead of trying to time it.

$ADMA I am going to use my words here to express how this makes me feel as I want to be mature and respectful about it. Difficult as it may be to articulate my thoughts, words like "hard," "tumescent," "erect," "throbbing," and "fortified" come to mind. Note that these words best describe my emotions, and shouldn't be muddied by the immaturity of some people participating on these forums who seem to always have their minds in the gutter. Good night everyone, 🥩

$ADMA SG-001 Development Remains on Track. ADMA continues to advance plasma collection optimization, potency assay development and preclinical activities supporting planned conformance lot production during the second half of 2026, ahead of the anticipated submission of its pre-Investigational New Drug (IND) meeting package to the U.S. Food and Drug Administration by year-end. Leveraging ADMA’s existing platform and commercial infrastructure, the Company believes it is positioned for a potentially rapid commercial ramp-up toward an approximately $300 to $500 million market opportunity. Hope we getting a bump up with any news on the above.

$ADMA I don't want to give too much attention to this issue, but I feel it affects a great number of people watching this stock, & the last thing I want is for anyone to feel marginalized because of their perfectly normal & healthy urges/orientation/preferences. When watching the share price drop over 3 percent with seemingly no bottom in sight, only to have it sharply reverse course & aggressively propel upwards, it is completely normal & healthy to feel the urge to evacuate your scrotum in a responsible & private way. Whether you work in an office environment or a Chick-fil-A, a simple "excuse me, I urgently need to visit the restroom" is all it takes to communicate to your manager that you are watching ADMA's share price perform some arousing acrobatics on the live chart, causing a perfectly natural biological response. Some people may even let out a yelp or soft moan upon completion due to the size of their holdings here, so running the water to muffle the sound may be helpful.

$ADMA Q2 was a success, let's wait and see how next quarter goes and if buybacks continue. 👍

$ADMA with all the misses in cardio and muscle it’s great to have a cash generating , de risked asset (Asceniv)

$ADMA ….hmm, just a little bit of a trend up. Has it reached bottom? Time to buy back in? Sol what I had in low 20’s.

$ADMA Here’s how ADMA’s the board and senior management manage shareholder relations in order to drive shareholder value: - The IR function is non existent. It’s outsourced and calls are never answered nor messages returned. - The company doesn’t attend investor conferences like its peers and like almost all companies do. That’s where new investors are identified - The company does not go on non deal roadshows to attract new investors . Typically the 4 sell side firms that follow the company would gladly take management around to meet new and existing accounts . This is how many new shareholders come on board. - On earnings calls management limits the number of questions from mainly the sell sided analysts . They try to hurry through the call. Thats simply ridiculous. - None of the CEO and senior executives have bought shares at these price levels . That in itself says plenty.

$ADMA popping off today, up nearly 8% Call buyers hit the November $11 strike hard We're seeing 2,342 contracts and about $129K in premium just today All ask-side sweeps, no puts Looks like they're betting on some upside into late November No fresh news driving this so it's looking like pure momentum Stock's up 3.2% over the last five days but without a clear catalyst, chasing these calls now feels risky Could see a pullback unless we get some solid follow-through soon Watch that $11 line for any signs of what's next

$ADMA in the midst of bitch carnage this bad boy holds strong . Granted at depressed levels .

$ADMA feels like Adam is really content to stay silent and ride the market. He’s rolling off cash and stock buybacks are cheaper at these levels. Smart investors will determine when the bottom is in.

$ADMA If you analyze the investors in detail on fintel.io, you’ll see that there have indeed been some interesting moves pointing toward activist tendencies.

$ADMA must be a bit uncomfortable for the shorts above. Definitely didn't wait until the end of day to yank it back down. Waiting for the pattern change 😉🍻

$ADMA you should just short this with all the money you have then. Short your life savings.

$ADMA quite the swan dive since I sold. Chart says no reason to buy except maybe luck out with a bottom fish.